Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03936465 |
|
Recruitment Status :
Active, not recruiting
First Posted : May 3, 2019
Last Update Posted : March 21, 2024
|
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Stand Up To Cancer
Information provided by (Responsible Party):
Steven DuBois, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | July 16, 2024 |
| Estimated Study Completion Date : | July 16, 2024 |